# Dechra Pharmaceuticals Plc Strong growth continuing in the USA

- Link: https://www.directorstalkinterviews.com/dechra-pharmaceuticals-plc-strong-growth-continuing-in-the-usa/412767855
- Published: 2019-02-25T07:57:42+00:00
- Author: Charlotte Edwards

**[Dechra Pharmaceuticals Plc](https://www.directorstalkinterviews.com/ftse-company/dechra-pharmaceuticals/dph.l)**(
LON:DPH) Half-Yearly Financial Report 2019 for the six months ended 31 December 
2018.

> “Trading across the Group has commenced well in the second half, with particularly
> strong growth continuing in the USA. Material synergies from the AST Farma and
> Le Vet acquisition will increase in the second half and initial indications are
> that our recent acquisition, Venco, is performing to our expectations.”
> **Ian Page, Chief Executive Officer**

**Highlights**
 · Trading in the Period was strong and in line with management expectations.·
Reported Group revenue for the Period increased by 19.1% at Constant Exchange Rate(
CER) (19.2% at Actual Exchange Rate (AER)). · European Pharmaceuticals (EU Pharmaceuticals)
revenue growth was 18.9% at CER (18.1% at AER). · North American Pharmaceuticals(
NA Pharmaceuticals) revenue growth was 19.3% at CER (21.0% at AER). · Underlying
operating profit growth was 28.0% at CER (28.2% at AER) with operating margin expansion
of 190 bps to 26.3%. · Reported operating profit declined mainly due to increased
amortisation of the acquired intangibles. · Strong cash conversion of 110.0% driven
by the expected unwinding of working capital. · AST Farma, Le Vet, RxVet and Caledonian
acquisitions performing well and in line with our expectations; acquisition of Laboratorios
Vencofarma do Brasil Ltda (Venco) completed. · Underlying diluted EPS growth of 
11.4% to 41.76 pence. Interim dividend increased by 29.6% to 9.5 pence.

**Financial Summary**

  |

Six months ended

31.12.18

£m

  |

Six months ended

31.12.17

£m

  |

Growth at

actual

exchange

 rate

  |

Growth at

constant

exchange

rate

  |  
 |

Revenue

  |

231.4

  |

194.1

  |

19.2%

  |

19.1%

  |  
 |

Underlying

  |

 |

 |

 |

 |  
 |

Operating profit

  |

60.8

  |

47.4

  |

28.2%

  |

28.0%

  |  
 |

Operating profit %

  |

26.3%

  |

24.4%

  |

190 bps

  |

190 bps

  |  
 |

EBITDA

  |

65.3

  |

51.0

  |

27.9%

  |

27.7%

  |  
 |

Diluted EPS

  |

41.76p

  |

37.58p

  |

11.1%

  |

11.4%

  |  
 |

Reported

  |

 |

 |

 |

 |  
 |

Operating profit

  |

17.0

  |

26.3

  |

(35.5%)

  |

(35.8%)

  |  
 |

Diluted EPS

  |

15.09p

  |

28.69p

  |

(47.4%)

  |

(47.4%)

  |

Share on:
